
Palantir Shows Huge, Unusual Put Options Trades - Investors Bullish on PLTR Stock
A Barchart report shows a large, unusual volume of put options in Palantir Inc. (PLTR) stock for expiration on Friday. The puts are out-of-the-money (OTM), implying investors are bullish on PLTR stock. For example, by shorting OTM puts, these investors can get paid by setting a lower potential buy-in price.
I discussed PLTR's recent rise in a Barchart article on Sunday, Feb. 16: ' Palantir Stock Keeps Rising, Confounding Analysts - What Should Investors Do? '
At the time, PLTR was at $119.16, but today it's trading for $123.11 at the market open. My article points out that analysts have been wrong so far on PLTR. I showed how it could be worth as much as $137.39 - although that may take some time.
Today's large volume in put options with strike prices below the trading price (i.e., out-of-the-money), implies that some investors are willing to buy large amounts of shares if PLTR falls to this lower price.
The Barchart Unusual Stock Options Activity Report— see below—shows two tranches of put options with heavy volume that expire on Friday, February. 21.
Investors Put Plays Show a Bullish Stance on PLTR Stock
For example, 14,653 put contracts, each representing 100 shares per contract, traded at $123.00, which is right at the market (ATM). This was 126 times the prior outstanding put contracts at this strike price.
However, the investors who sold these puts to the buyers have received a premium of $2.33 at the midprice. That means the breakeven price is 2% lower:
$123.00-$2.33 = $120.67 breakeven price
$120.67 / $123.11 trading price -1 = -.0198 = i.e., 2% below the trading price
Moreover, the investor's short-put yield at this strike price is almost 1.90%:
$2.33/$123 = 0.0189 = 1.89%
In addition, the second tranche has a lower strike price of $122, but the midprice premium was $1.94. That provides the short sellers a good yield of 1.59% and a lower breakeven:
$1.94 / $122 = 0.0159 = 1.59%
Breakeven = $122-$1.94 = $120.06 = 2.47% below trading price
The second tranche of puts has a better chance of not getting assigned, so the short-put yield is slightly lower. But consider this. The investors who sold these puts must be willing to have their account assigned to buy shares at $122, which is only $1.00 below today's trading price.
That is why there is a delta ratio of -69.53 - implying a good 70% chance this will happen. In other words, these investors are likely to have to buy shares at these strike prices.
That means they are bullish on PLTR stock.
Why PLTR Stock Keeps Rising
In my Feb. 16 Barchart article, I explained why PLTR is confounding analysts. The bottom line is that Palantir's free cash flow (FCF) growth and FCF margins are accelerating as its revenue rises.
That is known as operating leverage. That will push up its FCF margins even higher than its 63% level last quarter. As a result, the future value of PLTR stock, on a FCF yield basis, rises commensurately. I showed how this works in the article.
Analysts don't quite understand this, but many are waking up, as I pointed out. AnaChart's survey shows that the average of 15 analysts' price targets is $125.30.
I pointed out in my article that one way to play PLTR stock is to short deep out-of-the-money (OTM) put options. That way investors can get paid while potentially waiting for PLTR stock to drop to a lower buy-in level.
The bottom line is that PLTR stock is attracting large speculative activity today in put options activity. It shows that some large institutional investors are willing to buy the shares at roughly today's price, albeit getting paid in short-put plays at out-of-the-money breakeven prices.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
7 hours ago
- Globe and Mail
Better Buy: Palantir Stock vs. UnitedHealth Group Stock
Two stocks that have been at the center of financial news stories throughout the year are data mining specialist Palantir Technologies (NASDAQ: PLTR) and health insurance giant UnitedHealth Group (NYSE: UNH). The reasons these two companies are fetching so much attention, however, couldn't be more opposite. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Palantir has emerged as a darling of the artificial intelligence (AI) revolution. As of this writing (June 5), shares of the stock have gained nearly 60% on the year -- making it one of the top performers in the S&P 500 and Nasdaq-100 indexes. By contrast, UnitedHealth Group stock is the worst-performing name in the Dow Jones Industrial Average -- with shares plummeting by more than 40%. Is now the time to hop on the Palantir train, or should investors take an inventory check on UnitedHealth and choose to buy the dip? Palantir is on a run for the ages It's been just over two years since Palantir released its Artificial Intelligence Platform (AIP), a software suite that's proven to be a transformative game changer in the company's pursuit of competing with the largest players in the tech landscape. PLTR Revenue (Quarterly) data by YCharts Since releasing AIP, Palantir has unlocked a new wave of revenue acceleration -- thanks in large part to the company's impressive penetration of the private sector. For most of its history, Palantir relied heavily on government contracts from the Department of Defense (DOD). While deals with the U.S. Military and its allies are still an important cornerstone of Palantir's business, AIP has helped the company break ground in a host of other use cases -- financial fraud, supply chain and logistics, aviation, and much more. What might be most impressive about Palantir's transformation over the last two years is how rapidly the company transitioned from a cash-burning operation to one that generates consistent profitability. Not only is Palantir acquiring new business, but it's also monetizing these customers in a profitable way. That's a lucrative combination, indeed. The one idea that's paramount for smart investors to understand is that while Palantir's business is soaring, so is the company's share price. As of this writing, Palantir trades at a price-to-sales (P/S) ratio of 97. Not only is that magnitudes higher than any of its peers in the software realm, but it is historically high compared to what investors witnessed during the dot-com bubble in the late 1990s. I don't think I'm the only one who has noticed the pronounced valuation expansion in Palantir, either. Consider that Cathie Wood's Ark Invest portfolio has been trimming Palantir stock as of late, and billionaire money manager Stanley Druckenmiller completely dumped his firm's stake in the AI stock during the first quarter. UnitedHealth Group can't seem to get out of its own way UnitedHealth Group's coverage couldn't be any more different than Palantir's. While investors continue to cheer on Palantir's dominance, it seems that only negativity surrounds UnitedHealth at the moment. At the core of the health insurer's problems are some operational hiccups. Mismanagement in forecasting utilization rates in the company's Medicare Advantage business, as well as some unforeseen challenges in the pharmacy benefits management (PBM) segment, caused management to reduce financial guidance for 2025. If this weren't enough to get investors worked up, UnitedHealth also replaced its CEO as the company seeks to right the ship and turn things around by next year. UnitedHealth's downward revision and executive changes were met with a stock sell-off for the ages. Don't believe me? As of this writing, shares of UnitedHealth trade at $296 -- hovering near a five-year low. Which stock is the better buy? Despite its near-term headwinds, UnitedHealth stock looks awfully tempting at a forward price-to-earnings (P/E) multiple of just 13. When you consider that insiders have been buying the stock in the aftermath of this epic sell-off, I'm cautiously optimistic that all of the bad news surrounding UnitedHealth is priced in. UNH PE Ratio (Forward) data by YCharts On the other side of the equation, I think it's becoming increasingly difficult to argue that max upside isn't already priced into Palantir. Sure, I'm bullish on the company's future, but buying the stock near an all-time high doesn't seem like a prudent idea right now. Overall, I'd choose to buy the dip in UnitedHealth as opposed to chasing the momentum fueling Palantir stock at the moment. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adam Spatacco has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.


Globe and Mail
13 hours ago
- Globe and Mail
Is Palantir Still a Buy After Its Run-Up? 3 Analysts From The Motley Fool Weigh In.
One of the fastest-growing stocks in artificial intelligence (AI) over the last year is Palantir Technologies (NASDAQ: PLTR). Its Artificial Intelligence Platform (AIP) brought eye-popping productivity gains to its customers. Investors took notice, as the stock is up by 420% over the last year. Unfortunately for investors who have recently taken an interest, its forward P/E ratio is 205, and it sells for 96 times sales. Knowing that, three analysts from The Motley Fool have weighed in to determine whether its stock is still worth buying at these levels. Is Palantir a repeat lesson from the dot-com era? Justin Pope: Separating noise from signal is arguably the most challenging aspect of investing. For Palantir, the noise is a red-hot stock price. Shares of Palantir have risen a mind-melting 1,770% since 2023. In other words, buying the stock up to this point has looked like a genius move. Anyone seeing this, especially on social media, where people aren't always humble, might feel tempted to jump into the stock. But here is the signal. The stock is rising faster than Palantir's underlying business has grown. Don't get me wrong, I think Palantir is an excellent AI stock, and the company is executing at a high level, particularly since launching AIP two years ago. It can make a stock appear invincible when prices only go up. However, investors have seen this movie before. Cisco Systems ran to wildly excessive valuations during the infamous dot-com bubble in the late 1990s. It lost most of its value when the bubble burst, and still hasn't revisited its all-time high, a whopping 25 years later. That doesn't mean that Palantir will suffer the same fate, but check this out. Cisco's P/E ratio peaked at approximately 234, and its price-to-sales (P/S) ratio peaked at around 39. Palantir is even more expensive today than Cisco at its peak. CSCO data by YCharts At the very least, it's hard to imagine much more rational upside in Palantir from these levels. Even worse, any market downturn or misfire in Palantir's business could pop that valuation bubble. Investors should tread very carefully around Palantir stock these days. Amazon's stock history holds a valuable lesson for those worried about Palantir's lofty valuation Jake Lerch: Here's a sentiment that I often hear: "I love the stock, but it's too late to buy it now." And while there's nothing wrong with this viewpoint in theory, I've seen it disproven too many times in practice to grant it much weight. Take Amazon, for example. For years, countless analysts pointed out -- for good reason -- that Amazon's valuation was sky-high. From 1997 through 2000, Amazon's average P/S ratio was around 16. Moreover, the company had no profits -- and therefore no P/E ratio -- until 2003. Once it was making money, Amazon's average P/E ratio over its first five years of profitability was an eye-popping 88. Yet, investors who bought Amazon -- and held until today -- would be very happy with the results. In fact, $10,000 invested in the stock in 2008 would be worth about $800,000 today. This is all to point out that valuation isn't everything. Yes, Palantir is an expensive stock by just about any measure. Its current P/S and P/E ratios are significantly higher than the historical averages I cited for Amazon. However, that's because Palantir is poised to deliver enormous growth over the next decade or more. The company offers a unique value proposition that appeals to almost every organization. It can deliver efficiency gains for government agencies;it can cut costs for commercial clients. It can even help military and intelligence agencies win wars and prevent terrorist attacks. Simply put, there's very little this company can't do. Lastly, the nature of AI and data analysis means that Palantir is positioned to benefit from significant network effects and economies of scale as its AI systems improve and the company's overall client list grows. On top of that, its revenue is already growing at a year-over-year rate of 39%, andprofits are increasing, as is free cash flow. That's what gives me confidence to believe it's not too late to buy Palantir stock. Palantir is a winner for customers, but not investors Will Healy: When it comes to AI living up to its potential, perhaps no stock outshines Palantir. The company began in 2003 and utilizes AI and machine learning as a national security-focused tool. However, it was only when Palantir began to benefit from AIP's massive productivity gains that its popularity took off. Anduril Industries had a 200-fold efficiency gain in its ability to respond to supply shortages. A global insurer reduced an underwriting workflow from two weeks to three hours. With results like that, it is little wonder its commercial customer count is up fivefold over the past three years. Such gains undoubtedly played a role in the aforementioned stock price growth, but regrettably for Palantir bulls, the increases likely do not justify the software-as-a-service (SaaS) stock 's valuation, and here's why. In Q1, revenue of $884 million rose 39% compared to year-ago levels. With that growth, its net income of $214 million surged 103% higher over the same period. Unfortunately, triple-digit growth is not sustainable for even the best of companies, and the current valuation likely prices it for perfection. That "perfection" is likely not in the cards for Palantir. Analysts forecast revenue growth will slow to 36% for 2025 before falling to 29% in 2026. That is likely to do little to make the 96 P/S ratio more attractive, particularly when the larger and faster-growing Nvidia sells for 24 times sales. Indeed, Palantir is likely to play a key role in the AI field for years to come. Nonetheless, valuation matters at some point, and investors could find themselves stuck in a losing stock for years to come if the sentiment around the stock starts to turn negative. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jake Lerch has positions in Amazon and Nvidia. Justin Pope has no position in any of the stocks mentioned. Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Cisco Systems, Nvidia, and Palantir Technologies. The Motley Fool has a disclosure policy.


Globe and Mail
16 hours ago
- Globe and Mail
Prediction: 2 Nasdaq Stocks Will Be Worth More Than Palantir Technologies in 3 Years
Palantir Technologies stock has advanced 435% in the past year, bringing its market value to $300 billion as of June 7. But two Nasdaq stocks, Shopify (NASDAQ: SHOP) and Intuitive Surgical (NASDAQ: ISRG), are growing quickly enough to top that figure in three years. Here's what that would mean for shareholders: Shopify is currently worth $145 billion. It would achieve a market value of over $300 billion if its stock price increased 107% over the next three years, which implies annual returns of 27.4%. Intuitive Surgical is currently worth $200 billion. It would achieve a market value of over $300 billion if its stock price increased 50% in the next three years, which implies annual returns of 14.5%. Here's what investors should know about Shopify and Intuitive Surgical. 1. Shopify Shopify develops e-commerce software and services that help merchants run their businesses across multiple channels, including online marketplaces, social media, mobile apps, and branded websites. The company has won substantial market share. Its merchants account for over 12% of online retail sales in the U.S. and 6% in Western Europe. That makes Shopify the second-largest e-commerce company behind Amazon in those regions. Importantly, Forrester Research recently recognized Shopify as a technology leader in wholesale commerce (also known as business-to-business or B2B commerce) solutions. That's particularly encouraging because the wholesale commerce market is 4 times bigger and growing much more quickly than the retail commerce market, according to Grand View Research. Shopify reported reasonably good first-quarter financial results. Revenue increased 27% to $2.3 billion, and non-GAAP (generally accepted accounting principles) net income jumped 25% to $0.25 per diluted share. One encouraging metric was the 10- basis-point increase in take rate, which measures sales as a percentage of gross merchandise volume. A higher take rate indicates that merchants are adopting more add-on services, such as Shopify Payments. Wall Street expects adjusted earnings to increase by 23% annually through 2026. That makes the current valuation of 90 times earnings look rather expensive. However, analysts have usually underestimated the company. Shopify has beaten the consensus earnings estimate by an average of 11% over the last four quarters. If that trend continues, the stock price could increase by 107% (giving the company a market value above $300 billion) in the next three years while the valuation falls to a cheaper 85 times earnings. Admittedly, that is still an expensive valuation, which makes my prediction somewhat aggressive. But I think Shopify is an excellent long-term investment, even if it fails to top $300 billion within three years. 2. Intuitive Surgical Intuitive Surgical is the pioneer and leader in robotic-assisted surgery. It is best known for da Vinci systems, which enable surgeons to perform minimally invasive procedures with greater precision across several specialties, including urology, gynecology, and general surgery (e.g., hernia repair). The company also sells add-on instruments and accessories that must be replaced with each procedure, as well as supporting software for analytics and training. Intuitive Surgical reported solid first-quarter financial results. Revenue climbed 19% to $2.2 billion due to a combination of increased da Vinci procedure volume and higher systems placements. Meanwhile, non-GAAP net income increased 21% to $1.81 per diluted share. Intuitive Surgical has an important catalyst on the horizon in the midyear launch of its da Vinci 5 system, which features 10,000 times more computing power than its predecessor and innovations such as force feedback. Clinical evidence is still limited, but early data shows that force feedback technology may reduce the incidence of surgical trauma and promote faster recovery times. Importantly, Intuitive Surgical makes the vast majority of its systems in the U.S., but tariffs still represent a headwind because the company sources supplies globally and sells into foreign markets. Management estimates proposed tariffs will reduce its gross margin by 1.7 percentage points this year. But that figure leaves room for upside if the U.S. can negotiate trade deals. Wall Street expects adjusted earnings to grow at 10% annually through 2026, which makes the current valuation of 73 times earnings look very expensive. But analysts have regularly missed the mark. Intuitive Surgical beat the consensus estimate by an average of 14% over the last four quarters. If that continues, the stock could increase by 50% (giving the company a market value above $300 billion) over the next three years while the valuation falls to a more reasonable 65 times earnings. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in Amazon, Palantir Technologies, and Shopify. The Motley Fool has positions in and recommends Amazon, Intuitive Surgical, Palantir Technologies, and Shopify. The Motley Fool has a disclosure policy.